These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21841970)

  • 21. Application of induced pluripotent stem cell technology for the investigation of hematological disorders.
    Dolatshad H; Tatwavedi D; Ahmed D; Tegethoff JF; Boultwood J; Pellagatti A
    Adv Biol Regul; 2019 Jan; 71():19-33. PubMed ID: 30341008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reprogramming induced pluripotent stem cells in the absence of c-Myc for differentiation into hepatocyte-like cells.
    Li HY; Chien Y; Chen YJ; Chen SF; Chang YL; Chiang CH; Jeng SY; Chang CM; Wang ML; Chen LK; Hung SI; Huo TI; Lee SD; Chiou SH
    Biomaterials; 2011 Sep; 32(26):5994-6005. PubMed ID: 21658760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current advances in the generation of human iPS cells: implications in cell-based regenerative medicine.
    Revilla A; González C; Iriondo A; Fernández B; Prieto C; Marín C; Liste I
    J Tissue Eng Regen Med; 2016 Nov; 10(11):893-907. PubMed ID: 25758460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomaterial aided differentiation and maturation of induced pluripotent stem cells.
    Velmurugan BK; Bharathi Priya L; Poornima P; Lee LJ; Baskaran R
    J Cell Physiol; 2019 Jun; 234(6):8443-8454. PubMed ID: 30565686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of Induction: Induced Pluripotent Stem Cells (iPSCs).
    Singh VK; Kumar N; Kalsan M; Saini A; Chandra R
    J Stem Cells; 2015; 10(1):43-62. PubMed ID: 26665937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies.
    Jung YW; Hysolli E; Kim KY; Tanaka Y; Park IH
    Curr Opin Neurol; 2012 Apr; 25(2):125-30. PubMed ID: 22357218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integration-free reprogramming of human somatic cells to induced pluripotent stem cells (iPSCs) without viral vectors, recombinant DNA, and genetic modification.
    Heng BC; Fussenegger M
    Methods Mol Biol; 2014; 1151():75-94. PubMed ID: 24838880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of human iPSCs from cells of fibroblastic and epithelial origin by means of the oriP/EBNA-1 episomal reprogramming system.
    Drozd AM; Walczak MP; Piaskowski S; Stoczynska-Fidelus E; Rieske P; Grzela DP
    Stem Cell Res Ther; 2015 Jun; 6(1):122. PubMed ID: 26088261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of induced pluripotent stem cell technology.
    Zhou H; Ding S
    Curr Opin Hematol; 2010 Jul; 17(4):276-80. PubMed ID: 20442654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current reprogramming systems in regenerative medicine: from somatic cells to induced pluripotent stem cells.
    Hu C; Li L
    Regen Med; 2016 Jan; 11(1):105-32. PubMed ID: 26679838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induced pluripotent stem cells: fundamentals and applications of the reprogramming process and its ramifications on regenerative medicine.
    Walia B; Satija N; Tripathi RP; Gangenahalli GU
    Stem Cell Rev Rep; 2012 Mar; 8(1):100-15. PubMed ID: 21671061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association.
    Musunuru K; Sheikh F; Gupta RM; Houser SR; Maher KO; Milan DJ; Terzic A; Wu JC;
    Circ Genom Precis Med; 2018 Jan; 11(1):e000043. PubMed ID: 29874173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospects and Challenges of Induced Pluripotent Stem Cells in Equine Health.
    Donadeu FX; Esteves CL
    Front Vet Sci; 2015; 2():59. PubMed ID: 26664986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem Cells.
    Ng KM; Law CY; Tse HF
    J Clin Med; 2014 Oct; 3(4):1105-23. PubMed ID: 26237594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can controlled cellular reprogramming be achieved using microRNAs?
    Sun X; Fu X; Han W; Zhao Y; Liu H
    Ageing Res Rev; 2010 Oct; 9(4):475-83. PubMed ID: 20601195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induced Pluripotent Stem Cells (iPSCs) in Developmental Toxicology.
    Easley CA
    Methods Mol Biol; 2019; 1965():19-34. PubMed ID: 31069666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of nonsteroidal anti-inflammatory drug and anticancer drug enhancing reprogramming and induced pluripotent stem cell generation.
    Yang CS; Lopez CG; Rana TM
    Stem Cells; 2011 Oct; 29(10):1528-36. PubMed ID: 21898684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress in the reprogramming of somatic cells.
    Ma T; Xie M; Laurent T; Ding S
    Circ Res; 2013 Feb; 112(3):562-74. PubMed ID: 23371904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multimodal Therapeutic Effects of Neural Precursor Cells Derived from Human-Induced Pluripotent Stem Cells through Episomal Plasmid-Based Reprogramming in a Rodent Model of Ischemic Stroke.
    Oh SH; Jeong YW; Choi W; Noh JE; Lee S; Kim HS; Song J
    Stem Cells Int; 2020; 2020():4061516. PubMed ID: 32269595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review of induced pluripotent stem cell technology as a potential clinical therapy for spinal cord injury.
    Kramer AS; Harvey AR; Plant GW; Hodgetts SI
    Cell Transplant; 2013; 22(4):571-617. PubMed ID: 22944020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.